Chris Bulow, PhD

COO & Co-Founder

Chris built bioinformatic models of treatment resistant cell populations for two clinical trials during his PhD at Washington Univeristy in St. Louis. He built microfluidic organ systems for drug screening at Vanderbilt University. He led CMC, drug product manufacturing, and IND-enableing toxicology studies for a resistance blocking combination therapy.

Email: Chris Bulow